GET DAILY SIGNALSINmune Bio (INMB) Narrows Q3 Loss but Adjusts UK Regulatory Timeline
Key Takeaways
- INmune Bio reported a third-quarter net loss of approximately $4.7 million, narrowing from $6.5 million in the same period a year earlier.
- The company again recorded no product revenue, while both research and development (R&D) and general and administrative (G&A) expenses declined year over year.
- Management pushed its Ebstrocel™ UK regulatory submission to early February 2027, while still targeting potential UK approval in mid-2027.
- Cash and cash equivalents stood at about $16.3 million at quarter-end, and an October equity raise of $4.5 million extended the cash runway into the third quarter of 2027.
- The company is deferring significant spending on its XPro™ program until Ebstrocel receives approval, prioritizing resources behind its lead asset.
Why These Results Matter for Investors
INmune Bio is a late-stage biotechnology company focused on inflammation and immunology. Its quarterly updates provide insight into cash management and regulatory progress on Ebstrocel, its lead cellular therapy for recessive dystrophic epidermolysis bullosa (RDEB). With no approved products yet, attention centers on execution toward potential approval. I’m watching this closely because timelines, cash burn, and financing choices carry extra weight for a pre-revenue biotech.
Breaking Down the Reported Figures
For the third quarter ended September 30, 2026, INMB posted a net loss attributable to common stockholders of approximately $4.7 million, compared with roughly $6.5 million a year earlier. No product revenue was recorded. Research and development expenses came in at about $3.2 million, down from $4.9 million, while general and administrative expenses fell to approximately $1.8 million from $2.5 million. The narrower loss reflects reduced spending after winding down earlier Alzheimer’s trial work. The per-share loss improved to roughly $0.17 from $0.24. Cash and cash equivalents stood at approximately $16.3 million as of September 30. An October equity raise brought in about $4.5 million in gross proceeds, extending the runway into the third quarter of 2027. Roughly 31 million shares were outstanding as of November 5, 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Reacted
Shares of INMB moved lower after the release. Investors appeared to focus on the combination of a smaller loss, another delay in the UK filing, and the dilutive impact of the October offering. The revised UK Marketing Authorization Application target of early February 2027 drew notice, though management presented the shift as allowing for a more complete submission that could support quicker approval.
Key Items to Monitor Ahead
The near-term focus remains the UK MAA submission for Ebstrocel, now slated for early February 2027, with an expected MHRA response in three to six months and potential approval in mid-2027. In the US, plans include an FDA Type B meeting and a targeted BLA filing in mid-2027. The EMA pathway has been deprioritized. A partnership with Uniphar for named-patient access in select markets outside the US could generate early revenue, though no specific timing has been given. Spending on XPro will stay limited until Ebstrocel advances. Cash burn, any further financing, and the start of a confirmatory trial in early 2027 are also worth tracking.
Using AI Tools in My Research Process
One resource I turn to when reviewing names like this is Tickeron’s AI Screener. It helps me quickly scan for comparable companies using technical patterns, fundamentals, and AI signals, which adds useful context to the quarterly numbers without requiring hours of manual work. This approach has become a regular part of how I evaluate biotech opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INMB's RSI Oscillator stays in oversold zone for 2 days
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMB advanced for three days, in 200 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
INMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for INMB turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 47 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for INMB entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.602) is normal, around the industry mean (2.788). P/E Ratio (-1.895) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (714.286) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. INMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapies that harness the patient's immune system to treat cancer
Industry Biotechnology
Advertisement